Liver International Special Issue: Treatment of HCV with direct-acting antiviral agents: 100% cure?

Liver International

Full text articles are open access, see index of review articles below.

Special Issue:
Proceedings of the 11th Paris Hepatology Conference. International Conference on the Management of Liver Diseases

Proceedings of the 11th Paris Hepatology Conference. International Conference on the Management of Liver Diseases: 15–16 January 2018, Paris, France.

Begin here.....

Review Article
Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure?
Tarik Asselah, Patrick Marcellin, Raymond F. Schinazi

Full Text
View Online
Download PDF

Abstract
Around 71 million people are chronically infected with HCV worldwide. HCV antiviral drug development has been remarkable. The availability of pangenotypic direct-acting antivirals with excellent efficacy and good tolerability profiles offer a unique opportunity to achieve HCV elimination worldwide. IFN-free DAA combinations can now cure HCV in more than 95% of patients with HCV infection after 8-12 weeks of treatment. Programmes to eliminate HCV must include increased screening (risk-based and universal), linkage to care, as well as increased access to treatment worldwide. In this paper, we will review the available data on recently approved direct-acting antiviral agents, with sustained virological response that reaches almost 100%.

Continue to full text article

Index
REVIEW ARTICLES
Liver diseases: A major, neglected global public health problem requiring urgent actions and large-scale screening (pages 2–6)

Managing hepatitis C in patients with the complications of cirrhosis (pages 14–20)

Treatment of hepatitis C: Results in real life (pages 21–27)

Treatment of hepatitis C: the use of the new pangenotypic direct-acting antivirals in “special populations” (pages 28–33)

The next wave of hepatitis C virus: The epidemic of intravenous drug use (pages 34–39)

Is global elimination of HCV realistic? (pages 40–46)

Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: What we need in the future (pages 47–51)

Management of patients with non-alcoholic steatohepatitis (NASH) in real life (pages 52–55)

Future therapy for non-alcoholic fatty liver disease (pages 56–63)

Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Why liver biopsy is essential (pages 64–66)

Hepatitis B: Who and when to treat? (pages 71–78)

Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Non-invasive tests are enough (pages 67–70)

Treatment of hepatitis B: Is there still a role for interferon? (pages 79–83)

Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B (pages 84–89)